Galapagos NV (NASDAQ: GLPG) was established on June 30, 1999 and is headquartered in Belgium with 1,280 full-time employees. It is a clinical-stage biotechnology company focusing on the research and development of small molecule drugs and novel treatment methods to solve a large number of Medical needs, Galapagos’ breakthrough therapies and powerful product portfolio may completely change the existing disease treatment model.
Galapagos NV (GLPG):
Galapagos NV is a clinical-stage biotechnology company that discovers, develops and commercializes new drugs.
The Galapagos clinical phase plan includes:
- Filgotinib (GLPG0634)-in phase III clinical trials for the treatment of rheumatoid arthritis and Crohn’s disease; phase II/III trials for the treatment of ulcerative colitis; phase II clinical trials for multiple additional indications stage.
- GLPG1690, an autocrine motility factor inhibitor, is used in a phase III clinical trial for the treatment of idiopathic pulmonary fibrosis.
- GLPG1972, a phase Ib clinical trial for the treatment of osteoarthritis has been completed.
- MOR106 is in a phase II clinical trial for the treatment of atopic dermatitis.
Galapagos Company and Gilead Sciences signed a cooperation agreement to develop for filgotinib inflammation indications; and Servier (Servier) to develop GLPG1972; and AbbVie to develop and commercialize the treatment of cystic fibrosis and synergist for correction Molecule; cooperated with MorphoSys to develop MOR106; cooperated with Evotec AG to discover new targets for fibrosis and other indications.
Galapagos NV (GLPG) investment:
Galapagos NV will 2015-05-14 NASDAQ ticker symbol: GLPG, issue 380 million shares, financing 160.2 million US dollars, issue price of $ 42 / share, the same day the IPO as well as FTAI & FENX .
